All In Biotech

Drug Trial Radar · NCT02714595

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Last checked: Nov 20, 2026Latest source record: Jan 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

Sep 7, 2016

Primary completion

Apr 1, 2019

Study completion Apr 22, 2019

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Mar 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.

Conditions

  • Healthcare-associated Pneumonia (HCAP)
  • Bloodstream Infections (BSI)
  • Hospital Acquired Pneumonia (HAP)
  • Complicated Urinary Tract Infection (cUTI)
  • Sepsis
  • Ventilator Associated Pneumonia (VAP)

Interventions

  • CefiderocolDrug

    2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days, or 2 g every 6 hours for participants with creatinine clearance \>120 mL/min.

  • Best Available TherapyDrug

    Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/SepsisTime frame: Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21
  2. Percentage of Participants With Microbiologic Eradication at TOC in Participants With cUTITime frame: Test of cure, defined as 7 days after the end of treatment, equivalent to Study Days 14 to 21

Locations

85 sites in 16 countries. Site status is shown where the registry gives one.

  • Shionogi Research Site

    Hartford, Connecticut

  • Shionogi Research Site

    Newark, Delaware

  • Shionogi Research Site

    Chicago, Illinois

  • Shionogi Research Site

    New Orleans, Louisiana

  • Shionogi Research Site

    Detroit, Michigan

  • Shionogi Research Site

    Pittsburgh, Pennsylvania

  • Shionogi Research Site

    Salvador, Estado de Bahia, Brazil

  • Shionogi Research Site

    Curitiba, Paraná, Brazil

  • Shionogi Research Site

    Passo Fundo, Rio Grande do Sul, Brazil

  • Shionogi Research Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Shionogi Research Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Shionogi Research Site

    Santa Maria, Rio Grande do Sul, Brazil

  • Shionogi Research Site

    São José do Rio Preto, São Paulo, Brazil

  • Shionogi Research Site

    São Paulo, São Paulo, Brazil

  • Shionogi Research Site

    Split, Croatia

  • Shionogi Research Site

    Zagreb, Croatia

  • Shionogi Research Site

    Rijeka, Primorje-Gorski Kotar County, Croatia

  • Shionogi Research Site

    La Tronche, Auvergne-Rhône-Alpes, France

  • Shionogi Research Site

    Paris, Île-de-France Region, France

  • Shionogi Research Site

    Berlin, Germany

  • Shionogi Research Site

    Heidelberg, Baden-Wurttemberg, Germany

  • Shionogi Research Site

    Bonn, North Rhine-Westphalia, Germany

  • Shionogi Research Site

    Athens, Attica, Greece

  • Shionogi Research Site

    Athens, Attica, Greece

  • Shionogi Research Site

    Patra, Peloponnese, Greece

  • Shionogi Research Site

    Larissa, Thessaly, Greece

  • Shionogi Research Site

    Larissa, Thessaly, Greece

  • Shionogi Research Site

    Guatemala City, Guatemala

  • Shionogi Research Site

    Hadera, Israel

  • Shionogi Research Site

    Haifa, Israel

  • Shionogi Research Site

    Haifa, Israel

  • Shionogi Research Site

    Holon, Israel

  • Shionogi Research Site

    Jerusalem, Israel

  • Shionogi Research Site

    Beersheba, Beersheba, Israel

  • Shionogi Research Site

    Be’er Ya‘aqov, Rehoboth, Israel

  • Shionogi Research Site

    Tel Aviv, Tel Aviv, Israel

  • Shionogi Research Site

    Tel HaShomer, Tel Aviv, Israel

  • Shionogi Research Site

    Safed, Zefat, Israel

  • Shionogi Research Site

    Milan, Italy

  • Shionogi Research Site

    Milan, Italy

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.